knowledge -WSS

knowledge

author：knowledge 2025-10-01 02:15:57 - browse：6

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Medicare Advantage beneficiaries sue Humana over algorithm use

WSS

Why don't Americans have at

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Congress must protect the remaining independent doctors

ACIP vaccine advisory panel sees its vacancies filled

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Why Eli Lilly’s earnings didn’t quite live up to the hype

hotspot

knowledge

focus

23andMe had bad news about my health. I wish a person had delivered it

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Cancer drug shortages should be causing more outrage

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

SNAP should offer more nutrition education

Medicare details structure of new drug price negotiation program

Ebola vaccine can save some who are already sick, per new study

Peter Hotez and the public health issue of online harassment

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

Congress might make insulin pumps more accessible to the blind

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Why health care costs have stayed mostly flat since 2010

Virtual care provider acquires bankrupt Pear's prescription apps

Report cites 'urgent' need to recruit more diverse clinical trial participants

Keeping primary care docs in field isn't impossible, says AAFP CEO

hotspot

explore

focus

leisure time